GlassScriptPhysician profile
Boris Gurevich
NPI 1902877129
$4,971.31
in general payments reported to CMS, 2019-2025
40 companies · $193 in 2025
The $193 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,306 · 2020: $1,002 · 2021: $330 · 2022: $249 · 2023: $498 · 2024: $393 · 2025: $193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,068 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,068.41 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $539.70 | 2019-2025 | |
| Abbvie INC. | $467.94 | 2019-2024 | |
| Amarin Pharma, INC. | $349.08 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $339.61 | 2019 | |
| Allergan, INC. | $323.72 | 2019-2020 | |
| Lilly USA, LLC | $293.36 | 2019-2024 | Trulicity, Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $219.97 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $217.85 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $208.62 | 2019-2025 | |
| Novo Nordisk INC | $202.19 | 2021-2024 | Ozempic, Rybelsus |
| E.R. Squibb & Sons, L.L.C. | $194.71 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $194.13 | 2019-2024 | |
| Sunovion Pharmaceuticals INC. | $171.75 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.01 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $109.02 | 2019-2020 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Boris Gurevich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.